 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA, a patient-centric, pivitol-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system CNS in both rare and large patient populations, today announced its participation in a fireside chat for the BTIG Virtual Biotechnology Conference and a panel for the 2021 Wedbush Pacgrow Healthcare Virtual Conference. Conferences Detail 